EconPapers    
Economics at your fingertips  
 

Details about Jörg C. Mahlich

E-mail:
Homepage:http://www.xing.com/profile/Joerg_Mahlich
Workplace:Institut für Volkswirtschaftslehre (Department of Economics), Fakultät für Wirtschaftswissenschaften (Faculty of Economics), Universität Wien (University of Vienna), (more information at EDIRC)

Access statistics for papers by Jörg C. Mahlich.

Last updated 2022-07-13. Update your information in the RePEc Author Service.

Short-id: pma997


Jump to Journal Articles Books Edited books Chapters

Working Papers

2014

  1. Vergleichbarkeit internationaler Arzneimittelpreise: Internationale Preisreferenzierung in Deutschland durch das AMNOG
    DICE Ordnungspolitische Perspektiven, Heinrich Heine University Düsseldorf, Düsseldorf Institute for Competition Economics (DICE) Downloads View citations (1)
    See also Journal Article in Perspektiven der Wirtschaftspolitik (2015)

2006

  1. The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan
    MERIT Working Papers, United Nations University - Maastricht Economic and Social Research Institute on Innovation and Technology (MERIT) Downloads View citations (18)
    See also Journal Article in Review of Industrial Organization (2006)

2001

  1. The Changing Nature of Pharmaceutical R&D - Opportunities for Asia?
    Research Memorandum, Maastricht University, Maastricht Economic Research Institute on Innovation and Technology (MERIT) Downloads View citations (1)

Journal Articles

2022

  1. Estimation of Health-State Utility Values and Factors Driving Health-Related Quality of Life in People Living with HIV and AIDS and Receiving cART in Germany: Baseline Analysis of a Cohort Study
    Applied Research in Quality of Life, 2022, 17, (2), 851-869 Downloads

2021

  1. Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis
    Health Economics Review, 2021, 11, (1), 1-10 Downloads

2020

  1. Treatment patterns and healthcare resource utilization in palmoplantar pustulosis patients in Japan: A claims database study
    PLOS ONE, 2020, 15, (5), 1-18 Downloads

2019

  1. Patient and Physician Preferences for Therapy Characteristics for Psoriasis: A Discrete Choice Experiment in Japan
    PharmacoEconomics - Open, 2019, 3, (2), 255-264 Downloads
  2. Returns on different types of investment in the global pharmaceutical industry
    Managerial and Decision Economics, 2019, 40, (1), 16-36 Downloads View citations (2)

2018

  1. Treatment pathways of Japanese prostate cancer patients - A retrospective transition analysis with administrative data
    PLOS ONE, 2018, 13, (4), 1-15 Downloads

2017

  1. Cost of Illness of Japanese Patients with Chronic Lymphocytic Leukemia (CLL), and Budget Impact of the Market Introduction of Ibrutinib
    PharmacoEconomics - Open, 2017, 1, (3), 195-202 Downloads

2016

  1. Determinants of physician's office visits and potential effects of co-payments: evidence from Austria
    International Journal of Health Planning and Management, 2016, 31, (3), e192-e203 Downloads View citations (2)

2015

  1. Vergleichbarkeit internationaler Arzneimittelpreise
    Perspektiven der Wirtschaftspolitik, 2015, 16, (2), 164-172 Downloads
    See also Working Paper (2014)

2014

  1. Pharmaceutical regulation in Europe and its impact on corporate R&D
    Health Economics Review, 2014, 4, (1), 1-9 Downloads View citations (4)

2013

  1. Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany
    Applied Health Economics and Health Policy, 2013, 11, (5), 509-521 Downloads View citations (2)
  2. Erratum to: Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany
    Applied Health Economics and Health Policy, 2013, 11, (6), 689-689 Downloads View citations (2)
  3. Evaluating the concordance of physician judgments and patient preferences on AIDS/HIV therapy - a Discrete Choice Experiment
    Health Economics Review, 2013, 3, (1), 1-11 Downloads View citations (1)

2012

  1. Economic burden of osteoporotic fractures in Austria
    Health Economics Review, 2012, 2, (1), 1-10 Downloads View citations (1)

2011

  1. Intangibles Kapital und Rentabilität in der Pharmaindustrie
    Die Unternehmung - Swiss Journal of Business Research and Practice, 2011, 65, (1), 32-49 Downloads View citations (1)
  2. R&D MANAGEMENT OF JAPANESE PHARMACEUTICAL FIRMS
    International Journal of Innovation and Technology Management (IJITM), 2011, 08, (02), 211-226 Downloads

2010

  1. Patents and performance in the Japanese pharmaceutical industry: An institution-based view
    Asia Pacific Journal of Management, 2010, 27, (1), 99-113 Downloads View citations (8)

2006

  1. The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan
    Review of Industrial Organization, 2006, 28, (2), 145-164 Downloads View citations (18)
    See also Working Paper (2006)

2005

  1. Wirtschaftspolitik für wissensintensive Branchen am Beispiel der Pharmaindustrie
    Zeitschrift für Wirtschaftspolitik, 2005, 54, (3), 366-390 Downloads View citations (1)

Books

2006

  1. Das D-A-CH-Reformbarometer: Reformpolitik in Deutschland, Österreich und der Schweiz, vol 23
    IW-Analysen, Institut der deutschen Wirtschaft (IW) / German Economic Institute Downloads View citations (1)

Edited books

2012

  1. Korean Science and Technology in an International Perspective
    Springer Books, Springer View citations (4)

2007

  1. Innovation and Technology in Korea
    Springer Books, Springer View citations (15)

Chapters

2022

  1. Telemedicine in Japan: Challenges and Opportunities
    Springer

2007

  1. Introduction: Korea as a Newly Advanced Economy and the Role of Technology and Innovation
    Springer View citations (3)
  2. The Technological Competencies of Korea’s Firms: A Patent Analysis
    Springer
 
Page updated 2022-12-01